Sareum Holdings (LSE:SAR) ROCE % : -382.06% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sareum Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -382.06%.

Sareum Holdings ROCE % Historical Data

The historical data trend for Sareum Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings ROCE % Chart

Sareum Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-122.92

-75.60

-74.12

-72.33

-147.63

Sareum Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-48.01	-62.34	-95.95	-229.52	-382.06

Sareum Holdings ROCE % Calculation

Sareum Holdings's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-4.048	/	( ( (4.786 - 0.455)	+	(2.02 - 0.867) )	/ 2 )
	=	-4.048	/	( (4.331	+	1.153)	/ 2 )
	=	-4.048	/	2.742
	=	-147.63 %

Sareum Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-5.026	/	( ( (2.02 - 0.867)	+	(1.967 - 0.489) )	/ 2 )
	=	-5.026	/	( ( 1.153	+	1.478 )	/ 2 )
	=	-5.026	/	1.3155
	=	-382.06 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Sareum Holdings (LSE:SAR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sareum Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sareum Holdings (LSE:SAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RYH0:Germany

Address

Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX

Website

http://www.sareum.com

Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.